Beta Bionics, Inc.
Beta Bionics, Inc. (NASDAQ: BMNC) is a commercial-stage medical device company focused on designing, developing, and commercializing innovative solutions for insulin-requiring people with diabetes. The company's flagship product, the iLet Bionic Pancreas, received FDA clearance in May 2023 for treating Type 1 diabetes… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Beta Bionics, Inc. does
In the company’s own words
Beta Bionics, Inc. (NASDAQ: BMNC) is a commercial-stage medical device company focused on designing, developing, and commercializing innovative solutions for insulin-requiring people with diabetes. The company's flagship product, the iLet Bionic Pancreas, received FDA clearance in May 2023 for treating Type 1 diabetes in adults and children six years and older. As of December 31, 2025, the company had deployed approximately 35,011 iLets commercially in the United States.
The iLet represents a breakthrough in automated insulin delivery technology, functioning as the first and only insulin-delivery device that autonomously determines and delivers 100% of all insulin doses without requiring users to calculate boluses or count carbohydrates. The device integrates with leading continuous glucose monitors via Bluetooth and features an intuitive app-based interface with real-time updates and secure data-sharing capabilities for caregivers. The system comprises a pumping platform with single-use products, adaptive control algorithms, a touchscreen display, and a wirelessly rechargeable battery.
Beta Bionics manufactures and assembles the iLet at its primary facility in Irvine, California, which serves as the company's manufacturing and distribution center. The company maintains ISO 13485 certification and operates under current good manufacturing practices and Quality Management System Regulation requirements. The company markets and distributes the iLet through a direct commercial organization in the United States, concentrating initially on high-volume endocrinology practices with plans to expand into primary care settings.
The company pursues a multi-channel coverage and reimbursement strategy encompassing both the traditional durable medical equipment channel and the emerging pharmacy benefit plan channel to maximize patient access and generate recurring revenue. Beta Bionics' product development pipeline includes Mint, a next-generation tubeless insulin patch pump targeting commercial launch by the end of 2027, and a bihormonal iLet system designed to autonomously deliver both insulin and glucagon through an exclusive collaboration with Xeris Pharmaceuticals. The company also intends to pursue expanded use of the iLet for treating insulin-dependent Type 2 diabetes, representing a significant long-term market opportunity. More information is available at www.betabionics.com.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1674632
- SIC
- 3841
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Beta Bionics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Beta Bionics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Beta Bionics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Beta Bionics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Beta Bionics, Inc.'s last four quarterly filings that the numbers alone won't show?”